{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T08:25:45Z","timestamp":1794385545122,"version":"4.9.0"},"edition-number":"1","reference-count":237,"publisher":"Cambridge University Press","isbn-type":[{"value":"9780521896405","type":"print"},{"value":"9780511781926","type":"electronic"}],"license":[{"start":{"date-parts":[[2011,1,10]],"date-time":"2011-01-10T00:00:00Z","timestamp":1294617600000},"content-version":"unspecified","delay-in-days":53,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11,18]]},"DOI":"10.1017\/cbo9780511781926.010","type":"book-chapter","created":{"date-parts":[[2011,2,17]],"date-time":"2011-02-17T08:41:02Z","timestamp":1297932062000},"page":"155-183","source":"Crossref","is-referenced-by-count":0,"title":["Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and multiple myeloma"],"prefix":"10.1017","author":[{"given":"S. Vincent","family":"Rajkumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","reference":[{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1437","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase II, double blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1438","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.06.037"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1285","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204641"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1401","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5807"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1391","first-page":"402a","article-title":"High-dose melphalan and second autografts for myeloma relapsing after one autograft: results equivalent to tandem autotransplantation","volume":"98","author":"Sirohi","year":"2001","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1373","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1468","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.0294"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1324","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra030831"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1349","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.0221"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1322","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1258","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06235.x"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1361","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V108.11.56.56","article-title":"VELCADE\/dexamethasone (Vel\/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): an interim analysis of the IFM 2005-01 randomized multicenter phase III trial","volume":"108","author":"Harousseau","year":"2006","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1328","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie","year":"1999","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1448","first-page":"21","article-title":"Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients","volume":"98","author":"Fourney","year":"2003","journal-title":"J Neurosurg"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1278","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1182\/blood.V91.9.3518","article-title":"Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation","volume":"91","author":"Zent","year":"1998","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1261","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.9.2900"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1262","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04433.x"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1466","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)01137-8"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1463","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)88289-2"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1339","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood.V81.12.3382.3382","article-title":"Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]","volume":"81","author":"Greipp","year":"1993","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1287","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1182\/blood.V86.10.3915.bloodjournal86103915","article-title":"Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance","volume":"86","author":"Drach","year":"1995","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1280","first-page":"372","article-title":"Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma","volume":"14","author":"Dezube","year":"2004","journal-title":"AIDS Reader"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1283","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041875"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1356","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404801"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1294","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01929.x"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1290","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403555"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1462","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"Rajkumar","year":"2006","journal-title":"N Engl J Med"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1313","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.1087"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1472","doi-asserted-by":"publisher","DOI":"10.1016\/S0248-8663(05)80602-2"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1450","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1056\/NEJM198707163170315","article-title":"Multiple myeloma in naproxen-induced acute renal failure","volume":"317","author":"Wu","year":"1987","journal-title":"N Engl J Med"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1478","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70125-8"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1441","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.2465"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1493","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2299"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1266","first-page":"934a","article-title":"Prevalence of monoclonal gammopathy of undetermined significance (MGUS) among Olmsted County, MN residents 50 years of age","volume":"102","author":"Kyle","year":"2003","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1267","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3449"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1272","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404226"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1494","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood.V106.11.784.784","article-title":"Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy","volume":"106","author":"Wang","year":"2005","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1382","first-page":"42a","article-title":"Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg\/m2 + TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: results of Intergroup Trial S9321","volume":"102","author":"Barlogie","year":"2003","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1418","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000006303"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1486","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0801"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1353","first-page":"826","article-title":"First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma","volume":"89","author":"Cavo","year":"2004","journal-title":"Haematologica"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1489","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.147"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1397","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3869"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1460","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1614"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1388","first-page":"155a","article-title":"Superiority of double over single autologous stem cell transplantation as first-line therapy for multiple myeloma","volume":"104","author":"Cavo","year":"2004","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1301","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.6.1625"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1389","first-page":"S59","article-title":"Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM)","volume":"4","author":"Fermand","year":"2003","journal-title":"Hematol J"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1470","doi-asserted-by":"publisher","DOI":"10.1211\/0022357022241"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1337","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.6.1566"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1277","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood.V96.12.3880","article-title":"The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells","volume":"96","author":"Rawstron","year":"2000","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1426","unstructured":"Zangari M , Tricot G , Zeldis J , et al. Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT). Blood 2001:775a (A3226)."},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1396","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2955"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1365","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61537-2"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1310","doi-asserted-by":"crossref","first-page":"949a","DOI":"10.1182\/blood.V106.11.3396.3396","article-title":"The natural history of smoldering (asymptomatic) multiple myeloma","volume":"106","author":"Kyle","year":"2005","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1398","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404442"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1330","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1407","first-page":"2115","article-title":"A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma","volume":"9","author":"Gertz","year":"1995","journal-title":"Leukemia"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1332","first-page":"65","article-title":"Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patients","volume":"79","author":"Rapoport","year":"1990","journal-title":"S Afr Med J"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1297","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3811"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1379","first-page":"982a","article-title":"A phase II study of high dose 153-samarium EDMTP (153-Sm EDMTP) and melphalan for peripheral stem cell transplantation (PBSCT) in multiple myeloma (MM)","volume":"102","author":"Dispenzieri","year":"2003","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1279","doi-asserted-by":"publisher","DOI":"10.1086\/508351"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1399","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404459"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1362","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2546"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1359","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05540.x"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1273","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404225"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1492","doi-asserted-by":"publisher","DOI":"10.4065\/81.5.693"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1477","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50053"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1380","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1295","first-page":"176","article-title":"A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma","volume":"88","author":"Vacca","year":"2003","journal-title":"Haematologica"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1271","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1038"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1456","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.139"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1459","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106213442516"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1357","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405035"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1288","article-title":"Translocations at 14q32 are common in patients with the monoclonal gammopathy of undetermined significance (MGUS) and involve several partner chromosomes","volume":"94","author":"Fonseca","year":"1999","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1371","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1345","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)61029-X"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1425","first-page":"2552","article-title":"Velcade (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-term follow-up of phase I-II trial UARK 2001-37: superior outcome in patients with normal cytogenetics and no prior T","volume":"106","author":"Zangari","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1282","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2876"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1344","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015909"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1481","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood.V93.3.1032","article-title":"Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics","volume":"93","author":"Garcia-Sanz","year":"1999","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1485","doi-asserted-by":"publisher","DOI":"10.4065\/80.10.1371"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1321","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.57.1.43"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1384","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701805"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1471","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007309563"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1484","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.7.2229"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1408","first-page":"514a","article-title":"Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM)","volume":"96","author":"Barlogie","year":"2000","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1443","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2004.02.004"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1366","first-page":"75","article-title":"Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients \u2265 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01\/01","volume":"110","author":"Hulin","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1293","first-page":"2210","article-title":"Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis","volume":"8","author":"Rajkumar","year":"2002","journal-title":"Clin Cancer Res"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1429","doi-asserted-by":"crossref","first-page":"A7521","DOI":"10.1200\/jco.2006.24.18_suppl.7521","article-title":"Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009)","volume":"24","author":"Weber","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1464","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200009283431315"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1369","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68338-4"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1446","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.041131"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1417","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04473.x"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1377","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.731"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1367","first-page":"78","article-title":"Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial","volume":"110","author":"Waage","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1420","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.030"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1416","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200150"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1442","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1403","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-022962"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1335","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.7.2659"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1461","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0335"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1298","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403084"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1381","first-page":"685a","article-title":"Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM). Preliminary results of a prospective randomized trial (CIAM) protocol","volume":"88","author":"Facon","year":"1996","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1364","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3832"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1419","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200211000-00007"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1352","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.116"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1351","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1853"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1264","first-page":"1184","volume-title":"Cecil Textbook of Medicine","author":"Kyle","year":"2004"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1315","article-title":"Thalidomide alone or with dexamethasone for multiple myeloma","volume":"94","author":"Weber","year":"1999","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1475","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(98)00223-4"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1269","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.859"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1411","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.875"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1431","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.6-suppl_2-17"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1413","first-page":"124a","article-title":"Thalidomide frequently induces good partial remission and best response ever in patients with advanced multiple myeloma and prior high dose melphalan and autotransplant","volume":"94","author":"Juliusson","year":"1999","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1378","first-page":"S215","article-title":"166H0-DOTMP and high-dose melphalan before autologous peripheral blood stem cell transplantation in patients with multiple myeloma","volume":"4","author":"Bensinger","year":"2003","journal-title":"Hematol J"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1318","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403776"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1360","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study","volume":"91","author":"Harousseau","year":"2006","journal-title":"Haematologica"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1336","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)61797-2"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1325","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030847"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1479","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb05114.x"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1467","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701704613"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1340","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1428","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood.V106.11.6.6","article-title":"Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010)","volume":"106","author":"Dimopoulos","year":"2005","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1286","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1338","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1182\/blood.V91.7.2501","article-title":"Plasmablastic morphology\u2013an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group","volume":"91","author":"Greipp","year":"1998","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1476","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(01)00526-X"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1392","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701459"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1490","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50082"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1265","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/asheducation-2005.1.340","article-title":"MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management","author":"Rajkumar","year":"2005","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1289","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0761"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1385","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/028418600750063604","article-title":"Treatment approaches for relapsing and refractory multiple myeloma. [44 refs]","volume":"39","author":"Blade","year":"2000","journal-title":"Acta Oncologica"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1300","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403285"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1444","doi-asserted-by":"publisher","DOI":"10.4065\/81.8.1047"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1348","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood.V108.11.3563.3563","article-title":"A randomized comparison of dexamethasone + thalidomide (Dex\/Thal) vs dex + placebo (Dex\/P) in patients (pts) with relapsing multiple myeloma (MM)","volume":"108","author":"Fermand","year":"2006","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1480","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.4"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1390","first-page":"S61","article-title":"Single vs. tandem autologous transplantation in multiple myeloma: the GMMG experience","volume":"4","author":"Goldschmidt","year":"2003","journal-title":"Hematol J"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1434","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.558"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1405","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701559"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1329","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood.V95.12.4008","article-title":"Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities","volume":"95","author":"Desikan","year":"2000","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1393","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02726.x"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1421","first-page":"581","article-title":"Experience with long-term therapy using the proteasome inhibitor, bortezomib, in advanced multiple myeloma (MM)","volume":"22","author":"Berenson","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1449","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<142::AID-AJH10>3.0.CO;2-D"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1370","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-019778"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1368","doi-asserted-by":"crossref","first-page":"230a","DOI":"10.1182\/blood.V106.11.780.780","article-title":"Major superiority of melphalan\u2013prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma","volume":"106","author":"Facon","year":"2005","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1469","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2007.09.001"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1432","first-page":"236a","article-title":"An update of the use and outcomes of the new immunomodulatory agent CC-4047 (actimid) in patients with relapsed\/refractory myeloma","volume":"102","author":"Streetly","year":"2003","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1341","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1445","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1409","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.200"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1427","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0996"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1305","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402183"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1473","doi-asserted-by":"publisher","DOI":"10.1309\/6U88-357U-UKJ5-YPT3"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1455","doi-asserted-by":"publisher","DOI":"10.1177\/088506669501000304"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1316","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403905"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1435","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602223340802"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1281","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.ndt.a027215"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1311","first-page":"S31","article-title":"Risk factors for early progression of asymptomatic multiple myeloma","volume":"4","author":"Weber","year":"2003","journal-title":"Hematol J"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1296","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2441"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1415","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200326"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1451","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1990.00390160111022"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1284","doi-asserted-by":"publisher","DOI":"10.1038\/nrc746"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1374","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1424","first-page":"404","article-title":"The DOXIL-MMY-3001 Study Investigators. The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed\/refractory multiple myeloma compared with bortezomib alone: results from a planned interim analysis of a randomized phase III study","volume":"108","author":"Orlowski","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1354","doi-asserted-by":"publisher","DOI":"10.4065\/82.10.1179"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1386","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V89.3.789","article-title":"Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma","volume":"89","author":"Barlogie","year":"1997","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1422","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-036947"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1402","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3163"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1274","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404229"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1394","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04299.x"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1260","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12457-9"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1372","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.3463"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1474","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(00)00334-4"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1275","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403970"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1333","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1433","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1994.00420170079008"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1457","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.2.492"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1306","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood.V96.6.2037","article-title":"Solitary plasmacytoma of bone and asymptomatic multiple myeloma","volume":"96","author":"Dimopoulos","year":"2000","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1309","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04908.x"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1376","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)01077-5"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1346","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1270","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)60015-9"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1412","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.34"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1291","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403518"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1314","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402866"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1342","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1436","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1458","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405062"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1319","doi-asserted-by":"publisher","DOI":"10.4065\/80.10.1371"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1414","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04345.x"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1395","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2387"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1482","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.10.3082"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1302","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.159"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1440","doi-asserted-by":"publisher","DOI":"10.4065\/81.8.1100"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1308","first-page":"687a","article-title":"Abnormal MRI of spine is the dominant risk factor for early progression of asymptomatic multiple myeloma","volume":"102","author":"Wang","year":"2003","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1327","first-page":"418a","article-title":"Single versus double transplant in myeloma: a randomized trial of the \u201cInter Groupe Francais du Myelome\u201d (IFM)","volume":"90","author":"Attal","year":"1997","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1358","doi-asserted-by":"crossref","first-page":"100a","DOI":"10.1182\/blood.V104.11.336.336","article-title":"Phase II trial of single agent bortezomib (VELCADE\u00ae) in patients with previously untreated multiple myeloma (MM)","volume":"104","author":"Richardson","year":"2004","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1465","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.03.040"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1343","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2817"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1317","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2005.01.010"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1347","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0522"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1430","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90033-8"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1363","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1268","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa01133202"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1259","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains","volume":"48","author":"Katzmann","year":"2002","journal-title":"Clin Chem"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1276","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403647"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1439","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-2391(03)00720-1"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1307","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403857"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1483","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403256"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1320","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20652"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1400","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02857.x"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1491","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70124-6"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1331","first-page":"56","article-title":"Prognostic factors in multiple myeloma","volume":"2","author":"Kyle","year":"1995","journal-title":"Stem Cells"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1488","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50062"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1452","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430190059008"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1334","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70128-3"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1487","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1899"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1303","first-page":"717","article-title":"Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO)","volume":"89","author":"Barosi","year":"2004","journal-title":"Haematologica"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1263","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/clinchem\/48.4.655","article-title":"Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma","volume":"48","author":"Abraham","year":"2002","journal-title":"Clin Chem"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1292","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009910"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1326","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198302103080604"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1304","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1355","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1182\/blood.V108.11.799.799","article-title":"A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group","volume":"108","author":"Rajkumar","year":"2006","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1299","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-014563"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1423","first-page":"200","article-title":"Phase I study of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with refractory hematologic malignancies","volume":"22","author":"Orlowski","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1387","first-page":"5a","article-title":"Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the \u201cIntergroupe Francophone du Myelome\u201d (IFM 94)","volume":"100","author":"Attal","year":"2002","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1323","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2002.17.11.1921"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1454","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(95)00043-7"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1406","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-1-8"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1350","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood.V108.11.795.795","article-title":"A randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as primary therapy for newly diagnosed multiple myeloma","volume":"108","author":"Rajkumar","year":"2006","journal-title":"Blood"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1453","first-page":"738","article-title":"Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma.[Erratum appears in","volume":"114","author":"Dammacco","year":"2001","journal-title":"Br J Haematol"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1447","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-005-0021-y"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1404","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-101212"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1410","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.127"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1375","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0073"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1312","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1993.tb00148.x"},{"key":"9780511781926.CBO9780511781926A017_CBO9780511781926bib1383","first-page":"42a","article-title":"High-dose therapy autotransplantation\/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy. Definitive results from PETHEMA after a median follow-up of 66 months","volume":"102","author":"Blade","year":"2003","journal-title":"Blood"}],"container-title":["Management of Hematologic Malignancies"],"original-title":[],"link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/06486A388A0FFE7B86D6175A33058A6F","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T02:55:37Z","timestamp":1655088937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/CBO9780511781926A017\/type\/book_part"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,18]]},"ISBN":["9780521896405","9780511781926"],"references-count":237,"URL":"https:\/\/doi.org\/10.1017\/cbo9780511781926.010","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1017\/cbo9780511781926","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2010,11,18]]}}}